JP2018513107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513107A5 JP2018513107A5 JP2017542390A JP2017542390A JP2018513107A5 JP 2018513107 A5 JP2018513107 A5 JP 2018513107A5 JP 2017542390 A JP2017542390 A JP 2017542390A JP 2017542390 A JP2017542390 A JP 2017542390A JP 2018513107 A5 JP2018513107 A5 JP 2018513107A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutical composition
- disorder
- disease
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 239000004480 active ingredient Substances 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 6
- 208000027601 Inner ear disease Diseases 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 6
- 208000003251 Pruritus Diseases 0.000 claims 6
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 206010011224 Cough Diseases 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 3
- 206010021639 Incontinence Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010037660 Pyrexia Diseases 0.000 claims 3
- 208000026723 Urinary tract disease Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 230000017531 blood circulation Effects 0.000 claims 3
- 230000001079 digestive effect Effects 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 3
- 230000007954 hypoxia Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 230000028016 temperature homeostasis Effects 0.000 claims 3
- 208000014001 urinary system disease Diseases 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 0 *C(C1)=CC=C1C(C(N([C@@](C1)C(NCC(CC(c2cnc(C(F)(F)F)nc2)N=C2)=C2F)=O)C2(CC2)[C@@]1F)=N)=* Chemical compound *C(C1)=CC=C1C(C(N([C@@](C1)C(NCC(CC(c2cnc(C(F)(F)F)nc2)N=C2)=C2F)=O)C2(CC2)[C@@]1F)=N)=* 0.000 description 3
- KNUQIWPBVMPOGX-WILYLXEWSA-N C[C@@H]([C@@H](C[C@H]1C(NCc2cc(-c3cnc(C(F)(F)F)nc3)ncc2OC(F)(F)F)=O)F)N1S(c(cc1)ccc1F)(=O)=O Chemical compound C[C@@H]([C@@H](C[C@H]1C(NCc2cc(-c3cnc(C(F)(F)F)nc3)ncc2OC(F)(F)F)=O)F)N1S(c(cc1)ccc1F)(=O)=O KNUQIWPBVMPOGX-WILYLXEWSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015073102 | 2015-02-15 | ||
| CNPCT/CN2015/073102 | 2015-02-15 | ||
| CN2015076318 | 2015-04-10 | ||
| CNPCT/CN2015/076318 | 2015-04-10 | ||
| CNPCT/CN2016/071061 | 2016-01-15 | ||
| CN2016071061 | 2016-01-15 | ||
| PCT/EP2016/052950 WO2016128529A1 (en) | 2015-02-15 | 2016-02-12 | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513107A JP2018513107A (ja) | 2018-05-24 |
| JP2018513107A5 true JP2018513107A5 (enExample) | 2019-03-22 |
| JP6700291B2 JP6700291B2 (ja) | 2020-05-27 |
Family
ID=55349845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542390A Active JP6700291B2 (ja) | 2015-02-15 | 2016-02-12 | １−（ｈｅｔ）アリールスルホニル−（ピロリジン又はピペリジン）−２−カルボキサミド誘導体、及びｔｒｐａ１拮抗薬としてのそれらの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10179782B2 (enExample) |
| EP (1) | EP3256463B1 (enExample) |
| JP (1) | JP6700291B2 (enExample) |
| KR (1) | KR20170118166A (enExample) |
| CN (1) | CN107922392B (enExample) |
| AU (1) | AU2016217851A1 (enExample) |
| BR (1) | BR112017017052A2 (enExample) |
| CA (1) | CA2975196A1 (enExample) |
| CL (1) | CL2017001987A1 (enExample) |
| CO (1) | CO2017007679A2 (enExample) |
| CR (1) | CR20170367A (enExample) |
| EA (1) | EA033497B1 (enExample) |
| IL (1) | IL253478A0 (enExample) |
| MX (1) | MX2017010300A (enExample) |
| PE (1) | PE20180177A1 (enExample) |
| PH (1) | PH12017501478A1 (enExample) |
| PT (1) | PT3256463T (enExample) |
| SG (1) | SG11201706451TA (enExample) |
| TW (1) | TW201639829A (enExample) |
| WO (1) | WO2016128529A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI633087B (zh) | 2012-06-13 | 2018-08-21 | 赫孚孟拉羅股份公司 | 新穎二氮雜螺環烷及氮雜螺環烷 |
| RS59512B1 (sr) | 2012-09-25 | 2019-12-31 | Hoffmann La Roche | Derivati heksahidropirolo[3,4−c]pirola i srodna jedinjenja kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za lečenje npr. bubrežnih bolesti |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| WO2015078803A1 (en) | 2013-11-26 | 2015-06-04 | F. Hoffmann-La Roche Ag | NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL |
| CN106103446B (zh) | 2014-03-26 | 2019-07-30 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物 |
| KR20160128428A (ko) | 2014-03-26 | 2016-11-07 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물 |
| TWI676626B (zh) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | 抑制瞬時受體電位ａ１離子通道 |
| SG10201902963PA (en) | 2014-10-06 | 2019-05-30 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016144702A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| CN107592861B (zh) * | 2015-03-06 | 2021-06-08 | 法玛克亚公司 | 氟化赖氨酰氧化酶样2抑制剂及其用途 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| US20180186755A1 (en) * | 2015-07-01 | 2018-07-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| CN108026077B (zh) | 2015-09-04 | 2021-11-05 | 豪夫迈·罗氏有限公司 | 苯氧基甲基衍生物 |
| EP3353178B1 (en) | 2015-09-24 | 2021-07-14 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
| KR20180054635A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 억제제로서 이환형 화합물 |
| CR20180143A (es) | 2015-09-24 | 2018-05-03 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de atx/ca |
| PE20180461A1 (es) | 2015-09-24 | 2018-03-06 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de la atx |
| KR102766396B1 (ko) * | 2016-02-05 | 2025-02-13 | 이에이 파마 가부시키가이샤 | 복소환 술폰아미드 유도체 및 그것을 함유하는 의약 |
| EP3487849A1 (en) | 2016-07-20 | 2019-05-29 | H. Hoffnabb-La Roche Ag | Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators |
| CN109476640B (zh) * | 2016-07-20 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 双环脯氨酸化合物 |
| CN109803964A (zh) | 2016-08-12 | 2019-05-24 | 豪夫迈·罗氏有限公司 | 磺酰基吡啶基trp抑制剂 |
| WO2018048943A1 (en) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |
| CN109922803B (zh) | 2016-09-07 | 2023-09-22 | 法玛克亚公司 | 赖氨酰氧化酶样2抑制剂的用途 |
| HUE052205T2 (hu) | 2016-12-09 | 2021-04-28 | Vertex Pharma | Cisztás fibrózis transzmembrán vezetõképesség szabályzó modulátora, gyógyszerészeti készítmények, kezelési eljárások és eljárás a modulátor elõállítására |
| EP3554500A1 (en) | 2016-12-16 | 2019-10-23 | Galderma Research & Development | Trpa1 antagonists for use in the treatment of atopic dermatitis |
| JP7101177B2 (ja) | 2017-01-10 | 2022-07-14 | バイエル・アクチエンゲゼルシヤフト | 有害生物防除剤としてのヘテロサイクレン誘導体 |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
| BR112019025801A2 (pt) | 2017-06-08 | 2020-07-07 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| US11434201B2 (en) | 2017-08-02 | 2022-09-06 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| CA3085006A1 (en) * | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| AR114585A1 (es) | 2018-02-20 | 2020-09-23 | Hoffmann La Roche | Proceso para preparar compuestos antagonistas de canales potenciales transitorios del receptor de 1-arilsulfonil-pirrolidin-2-carboxamida y formas cristalinas de los mismos |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| WO2020116296A1 (ja) | 2018-12-07 | 2020-06-11 | ユニマテック株式会社 | 含フッ素ピリミジン化合物およびその製造方法 |
| CN110156834A (zh) * | 2019-06-05 | 2019-08-23 | 镇江市高等专科学校 | 一种黄色荧光铜(i)配合物及其制备方法和应用 |
| JP7471407B2 (ja) | 2020-05-19 | 2024-04-19 | ユニマテック株式会社 | 含フッ素ピリミジン化合物および含フッ素ピリミジノン化合物 |
| FR3114235A1 (fr) | 2020-09-18 | 2022-03-25 | Université Grenoble Alpes | Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer |
| CN116600787A (zh) * | 2020-11-19 | 2023-08-15 | 阿库西亚医疗有限责任公司 | 非水性凝胶组合物 |
| IT202100015098A1 (it) | 2021-06-09 | 2022-12-09 | Flonext S R L | Composto antagonista del canale trpa1 per uso in patologie degenerative della retina |
| US20250064846A1 (en) * | 2022-01-07 | 2025-02-27 | The Johns Hopkins University | Treatment and prevention of trigeminal neuralgia |
| AR131541A1 (es) | 2023-01-07 | 2025-04-09 | Syngenta Crop Protection Ag | Compuestos de carboxamida novedosos |
| WO2025109114A1 (en) | 2023-11-24 | 2025-05-30 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| WO2025149637A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025149629A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025155669A1 (en) * | 2024-01-17 | 2025-07-24 | The Jackson Laboratory | Trpc3 inhibitors and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010141805A1 (en) * | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
| EP2520566A1 (en) * | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
| JP6182072B2 (ja) | 2012-01-17 | 2017-08-16 | Ｅａファーマ株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
| JP6301842B2 (ja) * | 2012-12-18 | 2018-03-28 | Ｅａファーマ株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
| US9394308B2 (en) * | 2013-01-18 | 2016-07-19 | Merck Sharp & Dohme Corp. | Inhibiting the transient receptor potential A1 ion channel |
| TW201441225A (zh) * | 2013-01-18 | 2014-11-01 | Cubist Pharm Inc | 瞬時受體電位ａ１離子通道之抑制 |
| EP3055302B1 (en) * | 2013-10-11 | 2018-12-26 | F. Hoffmann-La Roche AG | Substituted heterocyclic sulfonamide compounds useful as trpa1 modulators |
| BR112016017317B1 (pt) | 2014-01-28 | 2023-04-11 | EA Pharma Co., Ltd | Composto, e, uso de um composto |
-
2016
- 2016-02-12 CR CR20170367A patent/CR20170367A/es unknown
- 2016-02-12 EP EP16703990.8A patent/EP3256463B1/en active Active
- 2016-02-12 US US15/042,310 patent/US10179782B2/en active Active
- 2016-02-12 CA CA2975196A patent/CA2975196A1/en not_active Abandoned
- 2016-02-12 PE PE2017001378A patent/PE20180177A1/es unknown
- 2016-02-12 KR KR1020177025946A patent/KR20170118166A/ko not_active Withdrawn
- 2016-02-12 CN CN201680009724.XA patent/CN107922392B/zh active Active
- 2016-02-12 WO PCT/EP2016/052950 patent/WO2016128529A1/en not_active Ceased
- 2016-02-12 MX MX2017010300A patent/MX2017010300A/es unknown
- 2016-02-12 EA EA201791836A patent/EA033497B1/ru not_active IP Right Cessation
- 2016-02-12 PT PT167039908T patent/PT3256463T/pt unknown
- 2016-02-12 BR BR112017017052-3A patent/BR112017017052A2/pt not_active IP Right Cessation
- 2016-02-12 JP JP2017542390A patent/JP6700291B2/ja active Active
- 2016-02-12 AU AU2016217851A patent/AU2016217851A1/en not_active Abandoned
- 2016-02-12 SG SG11201706451TA patent/SG11201706451TA/en unknown
- 2016-02-15 TW TW105104384A patent/TW201639829A/zh unknown
-
2017
- 2017-07-13 IL IL253478A patent/IL253478A0/en unknown
- 2017-07-28 CO CONC2017/0007679A patent/CO2017007679A2/es unknown
- 2017-08-03 CL CL2017001987A patent/CL2017001987A1/es unknown
- 2017-08-15 PH PH12017501478A patent/PH12017501478A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513107A5 (enExample) | ||
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2020073529A5 (enExample) | ||
| JP2018048154A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2020514318A5 (enExample) | ||
| TW201615219A (zh) | 呼吸系統疾病用藥臨床新應用 | |
| JP2015529234A5 (enExample) | ||
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| JP2009510044A5 (enExample) | ||
| MX2017003102A (es) | Formulacion para inhalacion liquida que comprende rpl554. | |
| EA201891931A1 (ru) | Новые ингибиторы фосфатидилинозитол-3-киназы гамма | |
| JP2016510326A5 (enExample) | ||
| JP2018521121A5 (enExample) | ||
| JP2016027060A5 (enExample) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| JP2017510607A5 (enExample) | ||
| JP2018537507A5 (enExample) | ||
| JP2017522300A5 (enExample) | ||
| JP2017105859A5 (enExample) | ||
| HRP20210294T1 (hr) | Postupci liječenja akutnog bubrežnog oštećenja |